Editorial: Nanomedicine development and clinical translation
Chuanqi Peng
DOI: https://doi.org/10.3389/fchem.2024.1458690
IF: 5.5
2024-10-09
Frontiers in Chemistry
Abstract:Nanomedicine, under the spotlight of biomedical research, has embraced rapid evolution and considerable accomplishments in the fundamental discovery and drug development for potential clinical translation. For the past decades, many novel concepts have been proposed by using engineered nanoparticles or nanomaterials for drug delivery, disease prevention, intervention and monitoring. Given the unique physicochemical properties, nanoparticles protect the payload (therapeutic or imaging agents, nucleic acids, etc.) from degradation, fine-tune the in vivo transport for targeting and clearance, modulate the controllable payload release. 1 From the very first FDAapproved nano-drug in 1995 -Doxil (in the form of PEGylated liposomal doxorubicin) 2 to now broadly applied lipid nanoparticle-based Covid-19 mRNA vaccines (under emergency use authorization in 2020), 3,4 nanomedicines have not only improved the life quality of patients bearing cancers, rare genetic disorders 5 and other diseases, but also protected healthy people effectively from viral infection and resulting complications. Over a hundred other candidates are being investigated in clinical trials as nanoparticle vaccines, therapies and diagnostics. 6 Meanwhile, the overall success rate falls short in the clinical translation of nanomedicines. And the clinically approved nanomedicines are mostly in the context of liposomes or lipid-based nanocarriers. In many research studies, the strategies in nanomedicine design, material synthesis and analytics often lack the consideration of translation potential or clinically relevant solutions. 7 Notably, the practice of transforming an interesting concept into a scalable, applicable and marketable medical product is quite challenging, as its development may be hampered or terminated at any time due to the limitations towards preclinical proof of concept, chemistry, manufacturing and controls (CMC), clinical safety and efficacy, regulatory compliance and even post-approval. So, nanomedicine researchers have recently concluded a series of developmental barriers to overcome, 8 including the formulation, toxicological, physiological, immunological, and translational barriers. More importantly, the successful clinical translation involves extensive collaborations with pharmaceutical, clinical and regulatory groups in the assessment of drug's critical quality attributes, pharmacokinetics, dosimetry, therapeutic index, cost-effectiveness as well as consideration of the complexity of a disease.We opened the Research Topic on Nanomedicine Development and Clinical Translation last year, aiming to better bridge the basic science research and clinical translation for current nanomedicine development. Herein, our hope is to receive the input from innovative researchers pinpointing the underlying challenges and opportunities of nanomedicine, so that clinical translation of nano-products may be accelerated become successful broadly.
chemistry, multidisciplinary